Assembly Biosciences, Inc.
As of Oct 22, 2026, Assembly Biosciences is in Stage 3, the topping phase, now in week 3 (since Oct 5, 2026). It closed at $20.28, 47.3% below its 52-week high and below its 200-day average, which is falling.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ASMB early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ASMB among Biotechnology276th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …276 | ASMB | Stage 3 · wk 3 | 34 | −15.4% |
Assembly Biosciences: quick answers
What stage is Assembly Biosciences in?
As of Oct 22, 2026, Assembly Biosciences (ASMB) is in Stage 3, the topping phase. It entered Stage 3 on Oct 5, 2026 and is in week 3. What the four stages mean
Is Assembly Biosciences in an uptrend?
Its uptrend has stalled. Assembly Biosciences is in Stage 3, the topping phase that follows an advance. It trades 26.4% below its 200-day average, which is falling.
How far is Assembly Biosciences from its 52-week high?
Assembly Biosciences closed at $20.28 on Oct 22, 2026, 47.3% below its 52-week high of $38.50. Its 52-week low is $20.09.
How has Assembly Biosciences performed over the past year?
As of Oct 22, 2026, Assembly Biosciences is down 28.6% over the past year and down 39.9% so far in 2026.
Which sector and industry is Assembly Biosciences in?
Assembly Biosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.